



A Pfizer Company

SAFETY DATA SHEET

Revision date: 16-Nov-2016

Version: 1.0

Page 1 of 10

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Gemcitabine Injection (Solution) (Hospira, Inc.)

Trade Name: Not applicable
Synonyms: Gemcitabine Injection
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against Intended Use: Pharmaceutical product used as Antineoplastic

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Skin Corrosion/Irritation: Category 3
Germ Cell Mutagenicity: Category 1B
Reproductive Toxicity: Category 1B

Label Elements

Signal Word: Danger
Hazard Statements: H316 - Causes mild skin irritation
H360FD - May damage fertility. May damage the unborn child.
H340 - May cause genetic defects

Precautionary Statements: P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P332 + P313 - If skin irritation occurs: Get medical advice/attention
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

SAFETY DATA SHEET

Material Name: Gemcitabine Injection (Solution) (Hospira, Inc.)

Page 2 of 10

Revision date: 16-Nov-2016

Version: 1.0



Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Gemcitabine hydrochloride	122111-03-9	Not Listed	Acute Tox. 2 (H302) Eye Irrit. 2B (H319) Skin Irrit. 2 (H315) Repr. 1B (H360FD) Muta. 1B (H340)	4.3
Sodium hydroxide	1310-73-2	215-185-5	Skin Corr.1A (H314)	**
Hydrochloric Acid	7647-01-0	231-595-7	STOT SE 3 (H335) Skin Corr. 1A (H314) Press. Gas Acute Tox. 3 (H331)	**

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Water for Injection	7732-18-5	231-791-2	Not Listed	*

Additional Information:

* Proprietary
 ** to adjust pH
 Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact:

Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact:

Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

SAFETY DATA SHEET

Material Name: Gemcitabine Injection (Solution) (Hospira, Inc.)

Page 3 of 10

Revision date: 16-Nov-2016

Version: 1.0

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of the spill if it is safe to do so. Absorb spills with non-combustible absorbent material and transfer into a labeled container for disposal.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize generating airborne mists and vapors. Avoid breathing dust, vapor or mist. Restrict access to work area. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product Antineoplastic

SAFETY DATA SHEET

Material Name: Gemcitabine Injection (Solution) (Hospira, Inc.)

Page 4 of 10

Revision date: 16-Nov-2016

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Sodium hydroxide

ACGIH Ceiling Threshold Limit:	2 mg/m ³
Australia PEAK	2 mg/m ³
Austria OEL - MAKs	2 mg/m ³
Bulgaria OEL - TWA	2.0 mg/m ³
Czech Republic OEL - TWA	1 mg/m ³
Estonia OEL - TWA	1 mg/m ³
France OEL - TWA	2 mg/m ³
Greece OEL - TWA	2 mg/m ³
Hungary OEL - TWA	2 mg/m ³
Japan - OELs - Ceilings	2 mg/m ³
Latvia OEL - TWA	0.5 mg/m ³
OSHA - Final PELs - TWAs:	2 mg/m ³
Poland OEL - TWA	0.5 mg/m ³
Slovakia OEL - TWA	2 mg/m ³
Slovenia OEL - TWA	2 mg/m ³
Sweden OEL - TWAs	1 mg/m ³
Switzerland OEL - TWAs	2 mg/m ³

Hydrochloric Acid

ACGIH Ceiling Threshold Limit:	2 ppm
Australia PEAK	5 ppm
	7.5 mg/m ³
Austria OEL - MAKs	5 ppm
	8 mg/m ³
Belgium OEL - TWA	5 ppm
	8 mg/m ³
Bulgaria OEL - TWA	5 ppm
	8.0 mg/m ³
Cyprus OEL - TWA	5 ppm
	8 mg/m ³
Czech Republic OEL - TWA	8 mg/m ³
Estonia OEL - TWA	5 ppm
	8 mg/m ³
Germany - TRGS 900 - TWAs	2 ppm
	3 mg/m ³
Germany (DFG) - MAK	2 ppm
	3.0 mg/m ³
Greece OEL - TWA	5 ppm
	7 mg/m ³
Hungary OEL - TWA	8 mg/m ³
Ireland OEL - TWAs	5 ppm
	8 mg/m ³
Italy OEL - TWA	5 ppm
	8 mg/m ³
Japan - OELs - Ceilings	2 ppm
	3.0 mg/m ³
Latvia OEL - TWA	5 ppm
	8 mg/m ³

SAFETY DATA SHEET

Material Name: Gemcitabine Injection (Solution) (Hospira, Inc.)

Page 5 of 10

Revision date: 16-Nov-2016

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Lithuania OEL - TWA	5 ppm 8 mg/m ³
Luxembourg OEL - TWA	5 ppm 8 mg/m ³
Malta OEL - TWA	5 ppm 8 mg/m ³
Netherlands OEL - TWA	8 mg/m ³
Poland OEL - TWA	5 mg/m ³
Portugal OEL - TWA	5 ppm 8 mg/m ³
Romania OEL - TWA	5 ppm 8 mg/m ³
Slovakia OEL - TWA	5 ppm 8.0 mg/m ³
Slovenia OEL - TWA	5 ppm 8 mg/m ³
Spain OEL - TWA	5 ppm 7.6 mg/m ³
Switzerland OEL - TWAs	2 ppm 3.0 mg/m ³
Vietnam OEL - TWAs	5 mg/m ³

Gemcitabine hydrochloride

Pfizer Occupational Exposure Band (OEB): OEB 5 - Skin (control exposure to <1ug/m³, provide additional precautions to protect from skin contact)

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section. It is recommended that all operations be fully enclosed and no air recirculated.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Hands:

Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)

Eyes:

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin:

Wear impervious protective clothing to prevent skin contact – consider use of disposable clothing where appropriate. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Respiratory protection:

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.)

SAFETY DATA SHEET

Material Name: Gemcitabine Injection (Solution) (Hospira, Inc.)

Page 6 of 10

Revision date: 16-Nov-2016

Version: 1.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Sterile solution	Color:	No data available.
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water solubility:	15.3 g/L (gemcitabine)
Water Solubility:	No data available
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)	

Hydrochloric Acid

No data available

Sodium hydroxide

No data available

Water for Injection

No data available

Gemcitabine hydrochloride

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s):	No data available
Vapor Pressure (kPa):	No data available
Vapor Density (g/ml):	No data available
Relative Density:	No data available
Viscosity:	No data available

Flammability:

Autoignition Temperature (Solid) (°C):	No data available
Flammability (Solids):	No data available
Flash Point (Liquid) (°C):	No data available
Upper Explosive Limits (Liquid) (% by Vol.):	No data available
Lower Explosive Limits (Liquid) (% by Vol.):	No data available

10. STABILITY AND REACTIVITY

Reactivity:	No data available
Chemical Stability:	Stable under normal conditions of use.
Possibility of Hazardous Reactions	
Oxidizing Properties:	No data available
Conditions to Avoid:	Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products:	No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: May be absorbed through the skin and cause systemic effects.

SAFETY DATA SHEET

Material Name: Gemcitabine Injection (Solution) (Hospira, Inc.)

Page 7 of 10

Revision date: 16-Nov-2016

Version: 1.0

11. TOXICOLOGICAL INFORMATION

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on reproductive system, and blood and blood forming organs. Animal studies have shown a potential to cause adverse effects on the fetus.

Known Clinical Effects: Adverse effects associated with therapeutic use include decreased blood cell count, nausea, vomiting, swelling, skin rash, liver enzyme changes, flu-like syndrome.

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium hydroxide

Mouse IP LD50 40 mg/kg

Gemcitabine hydrochloride

Mouse Oral Minimum Lethal Dose 333 mg/kg

Rat Oral LD50 > 500mg/kg

Rabbit Dermal LD50 > 1000mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium hydroxide

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Severe

Gemcitabine hydrochloride

Skin Irritation Rabbit Irritant

Eye Irritation Rabbit Irritant

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Gemcitabine hydrochloride

6 Month(s) Dog No route specified 0.04 mg/kg/day NOAEL Blood, Erythroid cells, Lymphoid tissue, Immune system

6 Month(s) Mouse No route specified 0.006 mg/kg/day LOAEL Erythroid cells, Male reproductive system, Spleen

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Gemcitabine hydrochloride

Reproductive & Fertility Mouse Intraperitoneal 0.05 mg/kg/day NOAEL Fertility

Fertility and Embryonic Development Mouse Intravenous 0.25 mg/kg/day LOAEL Fetotoxicity, Embryotoxicity, Maternal Toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Gemcitabine hydrochloride

In Vivo Micronucleus Mouse Positive

In Vitro Mammalian Cell Mutagenicity Mouse Lymphoma Positive

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative

In Vivo Sister Chromatid Exchange Negative

In Vitro Chromosome Aberration Negative

SAFETY DATA SHEET

Material Name: Gemcitabine Injection (Solution) (Hospira, Inc.)

Page 8 of 10

Revision date: 16-Nov-2016

Version: 1.0

11. TOXICOLOGICAL INFORMATION

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Hydrochloric Acid
IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity:
Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Gemcitabine hydrochloride

Oncorhynchus mykiss (Rainbow Trout) LC50 96 Hours > 1043 mg/L
Pimephales promelas (Fathead Minnow) LC50 96 Hours > 1014 mg/L
Daphnia Magna (Water Flea) EC50 48 Hours > 999 mg/L
Selenastrum capricornutum (Green Alga) EC50 5.4 mg/L

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Gemcitabine hydrochloride

Nostoc sp. (Freshwater Cyanobacteria) MIC 800 mg/L
Aspergillus niger (Fungus) MIC > 1000 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

SAFETY DATA SHEET

Material Name: Gemcitabine Injection (Solution) (Hospira, Inc.)

Page 9 of 10

Revision date: 16-Nov-2016

Version: 1.0

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Gemcitabine hydrochloride

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Sodium hydroxide

CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	1000 lb
California Proposition 65	454 kg
Inventory - United States TSCA - Sect. 8(b)	Not Listed
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 5
EU EINECS/ELINCS List	Schedule 6
	215-185-5

Hydrochloric Acid

CERCLA/SARA 313 Emission reporting	1.0 %
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	5000 lb
CERCLA/SARA - Section 302 Extremely Hazardous TPQs	2270 kg
CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs	500 lb
California Proposition 65	5000 lb
Inventory - United States TSCA - Sect. 8(b)	Not Listed
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Present
EU EINECS/ELINCS List	Schedule 5
	Schedule 6
	231-595-7

Water for Injection

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

SAFETY DATA SHEET

Material Name: Gemcitabine Injection (Solution) (Hospira, Inc.)

Page 10 of 10

Revision date: 16-Nov-2016

Version: 1.0

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; Skin corrosion/irritation-Cat.2; H315 - Causes skin irritation
Germ cell mutagenicity-Cat.1B; H340 - May cause genetic defects
Reproductive toxicity-Cat.1B; H360FD - May damage fertility. May damage the unborn child.
Serious eye damage/eye irritation-Cat. 2B; H319 - Causes serious eye irritation
Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage
Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation
Acute toxicity, inhalation-Cat.3; H331 - Toxic if inhaled

Data Sources: Publicly available toxicity information. Safety data sheets for individual ingredients.

Reasons for Revision: New data sheet.

Revision date: 16-Nov-2016
Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet